New effective combination therapy for pediatric acute cell leukemia and drug news

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children. The form of T-ALL leukemia that arises from cells of the early T lineage has a worse prognosis than all of the B lineage. The prognosis for frequent T-ALL is very poor and new therapies are necessary. A joint study by the Tampere University School of Medicine and Health Technology in Finland, the Massachusetts Institute of General Research and the Harvard Stem Cell Institute has found a new drug combination effective against T-ALL.

This finding builds on previous findings from the University of Tampere research group in which the general tyrosine kinase inhibitor dasatinib was found to be effective in about a third of patient samples tested.

In the treatment of leukemia, the effectiveness of a single drug is usually quickly lost, so the new study looked for combinations of drugs that would have an increased synergistic effect with dasatinib. This was the case with Temsirolimus, a drug that inhibits the parallel signaling pathway. The combination of the two drugs was more effective in eliminating leukemia cells in zebrafish and human diseases than using a single drug.

“During this study, we developed a novel drug screening method for the rapid assessment of drug responses in zebrafish leukemia samples. In this screen, an effective drug combination was found, which was subsequently confirmed by multiple cell line models, patient samples, and carcinomas. Human blood was bred on mice, says Dr. Sarah Laukkanen, first author of the study.

“It was a long project, lasting 4-5 years, and as a result, we now understand the mechanism of action of these drugs at the molecular level in T-ALL,” adds Laukkanen.

During the project, she spent six months as a visiting scientist in the Department of Pathology at Massachusetts General Hospital in Boston with the research group of Professor David Langenau, with whom the project was carried out. I worked extensively with PhD student Alexandra Veloso, researcher on the Langenau team and co-lead author of the work.

“This is a promising new treatment option for acute T-cell leukemia. The next step is to translate the discovery into clinical practice for patients with relapsed or refractory disease through early clinical trials,” says Director of Research Ole Lohi, MD, PhD, of the Center for Disease Control and Prevention. Cancer University of Tampere and Thaies Hospital.

“The development of microprocessors is slow and requires careful knowledge of the molecular mechanisms that cause and maintain disease. Here, we used a specific dependence of T-ALL cells on specific signaling pathways that are interrupted by the combination of dasatinib and temsirolimus,” says Lohi. .

The study was published in the blood. In addition to researchers from the University of Tampere and the Harvard Stem Cell Institute, researchers from the universities of North Carolina, Eastern Finland and Helsinki were also involved in the study.

Story source:

Material provided by University of Tampere. Note: Content can be modified according to style and length.

#effective #combination #therapy #pediatric #acute #cell #leukemia #drug #news

Leave a Comment

Your email address will not be published.